Drugs / εPA-44
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02862106 | Sep 2010 → Mar 2013 | chronic hepatitis B virus infection | Chongqing Jiachen Biotechnology Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT01326546 | Jun 2010 → Jan 2014 | chronic hepatitis B virus infection | Chongqing Jiachen Biotechnology Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT00869778 | Apr 2009 → Nov 2011 | chronic hepatitis B virus infection | Chongqing Jiachen Biotechnology Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | εPA-44 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02862106 ↗ |
| Known as | Therapeutic HBV vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01326546 ↗ |
| Modality | Vaccine | “a de novo designed liposome-based nanoparticle lipopeptide vaccine, εPA-44” PMID 34396571 ↗ Dec 2021 |
| Route | Subcutaneous | “six subcutaneous injections of 600 µg or 900 µg εPA-44 or placebo at week 0, 4, 8, 12, 20, and 28.” PMID 34396571 ↗ Dec 2021 |